2 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访  业绩说明会 | | 投资者关系活动类别 | 新闻发布会 □路演活动 | | | 现场参观 | | | 其他 | | 参与单位名称及人员姓名 | 投资者网上提问 | | 时间 | 2023 年 5 月 15 日 (周一) 下午 14:00-16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开业绩说明会 | | 上市公司接待人员姓名 | 1、财务负责人吴春红女士 | | | 2、董事会秘书周广阔先生 | | 形式 | 文字交流 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问二季度以来公司的经营情况如何？ | | | 答：您好，自 23 年年初以来公司经营情况良好，业绩指标符合预期。感谢 | | | 关注！ | | | 2、为什么每年第三季度的业绩特别差呢？ | | | 答：您好，公司部分品类的产品存在季节性特点。谢谢。 | | | 3、实控人目 ...

证券代码：002737 证券简称：葵花药业 公告编号：2023-021 葵花药业集团股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，葵花药业集团股份有限公司(以下简称 "公司")将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下: 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (http://rs.p5w.net)；或关注微信公众号(名称:全景财经)；或下载全景路演 APP,参与本次互动交流。活动时间为 2023 年 5 月 15 日(周一) 14:00-16:30。届 时公司董事会秘书周广阔先生、公司财务负责人吴春红女士将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续发展 等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与! 特此公告。 葵花药业集团股份有限公司 ...

1 | 3、业绩能保持多久，谢谢？ | | --- | | 答：公司未来将坚持既定战略，充分发挥公司品牌影响力大、品种种类丰 | | 富、以及团队战斗力强的优势，持续保持公司的市场竞争力。 | | 4、二季度业绩能继续保持高增长？ | | 答：公司将按照既定战略落地经营计划，谢谢！ | | 5、请问，葵花会不会大举进军保健品行业？ | | 答：大健康产业是公司药品业务的重要补充和未来的重要增长点之一。 | | 6、（1）公司老董事长从 2019 年至今一直在连续减持本公司股票是出于什 | | 么原因？（2）公司留存的大量现金未来还会继续进行现金理财吗？是否考 | | 虑股票基金等产品的投资？是否考虑提高分红比例？（3）管理层认为公司 | | 自身能够保持连续增长的原因是什么？未来会如何继续扩张？ | | 答：1、公司老董事长减持股份主要原因为个人资金需求；2、公司会在综 | | 合考虑安全性和收益性基础上对公司的现金进行管理，公司将在稳健经营 | | 的基础上尽可能保持分红政策的稳定性和连续性；3、公司未来将坚持既定 | | 战略，充分发挥公司品牌影响力大、品种储备丰富以及团队战斗力强的优 | | 势，持续保 ...

3.第一季度报告是否经审计 | --- | --- | --- | --- | --- | |---------------------------------------------|---------------|---------------|---------|------------------------------------| | 适用 □不适用 \n资产负债表项目 \n项 目 | 期末余额 | 年初余额 | 变动比 | 单位：元 \n变动原因说明 | | 应收款项融资 | 18,286,786.90 | 32,269,107.04 | -43.33% | 主要系报告期承兑汇票到期解付所致。 | | 其他流动资产 | 2,731,748.20 | 11,026,737.82 | -75.23% | 主要系报告期待验的原材料重分类所 | （二） 公司优先股股东总数及前 10 名优先股股东持股情况表 6 葵花药业集团股份有限公司 2023 年第一季度报告 葵花药业集团股份有限公司 （一） 主要会计数据和财务指标 二、股东信息 （一） 财务报表 8 2023 年第一季度报告 本公司及董事会全体成员保 ...

Financial Performance - The company reported a total revenue of 5.84 billion CNY for the year 2022, reflecting a year-on-year increase of 10%[19] - The company's operating revenue for 2022 was approximately ¥5.09 billion, representing a 14.20% increase from ¥4.46 billion in 2021[30] - The net profit attributable to shareholders for 2022 was approximately ¥867.19 million, a 23.05% increase from ¥704.74 million in 2021[30] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥804.19 million, reflecting a 32.20% increase from ¥608.33 million in 2021[30] - The net cash flow from operating activities for 2022 was approximately ¥1.97 billion, a significant increase of 127.78% from ¥865.23 million in 2021[30] - The basic earnings per share for 2022 was ¥1.48, up 22.31% from ¥1.21 in 2021[30] - The total assets at the end of 2022 were approximately ¥7.03 billion, a 24.78% increase from ¥5.64 billion at the end of 2021[30] - The net assets attributable to shareholders at the end of 2022 were approximately ¥4.20 billion, a 13.35% increase from ¥3.71 billion at the end of 2021[30] - The weighted average return on net assets for 2022 was 21.98%, compared to 20.49% in 2021[30] - The company reported a significant increase in quarterly revenue, with Q4 2022 revenue reaching approximately ¥1.87 billion[47] Profit Distribution and Dividends - The profit distribution plan approved by the board includes a cash dividend of 10 CNY per 10 shares, totaling 584 million CNY to be distributed to shareholders[19] - The company did not propose a cash dividend distribution plan despite reporting a positive profit available for distribution to shareholders[88] - The company has not made any adjustments to its dividend distribution policy during the reporting period, adhering to the established plan[110] Market Strategy and Expansion - The company is focusing on expanding its market presence and enhancing its product offerings through new product development and technological advancements[3] - Future strategic plans include potential mergers and acquisitions to strengthen market position and diversify product lines[3] - The company aims to increase user engagement and customer base through targeted marketing strategies and improved service delivery[3] - The company plans to leverage its subsidiaries to enhance operational capabilities and drive growth in various regions[3] - The company is focusing on expanding its children's medication product line, particularly in areas such as fever and pain relief, digestion, and respiratory drugs[179] - The company is exploring partnerships for strategic cooperation to enrich its product resource pool and expand its market presence[157] - The strategic focus for 2023 includes enhancing brand recognition and targeting specific consumer groups to drive growth, particularly in the children's medication sector[156] Risks and Challenges - The company faces risks including industry policy changes, raw material price fluctuations, and intensified market competition, which may impact future performance[3] - The board of directors has highlighted the importance of investor awareness regarding potential investment risks associated with forward-looking statements[18] - The company recognizes risks related to industry policy changes and raw material price fluctuations, and is implementing measures to strengthen management and internal controls[164] - The company is facing increased market competition risks, particularly in the traditional Chinese medicine sector, and is implementing measures to enhance organizational vitality and talent retention[182] Research and Development - R&D investment decreased by 28.36% from 132,065,176.99 CNY in 2021 to 94,614,417.97 CNY in 2022, representing 1.86% of operating revenue[102] - The company has not capitalized any R&D expenditures in both 2021 and 2022, maintaining a 0.00% capitalization rate[102] - The company has reduced its R&D personnel by 16.26% from 535 in 2021 to 448 in 2022, with a notable increase in the proportion of undergraduate degree holders[186] - The company is focusing on developing probiotics for health food registration to enhance its technological barriers[199] - The company aims to obtain production licenses for multiple new drugs to expand its product offerings in various therapeutic areas[199] Product Development and Offerings - The company is focusing on expanding its children's medication line, with products like "小葵花" achieving competitive advantages in the market[63] - The company plans to enhance its adult medication offerings, particularly in chronic disease and women's health products, while maintaining a strong market share in core products[64] - The company is implementing a differentiated brand strategy to strengthen its brand influence, with "小葵花" recognized as a leading children's medication brand in the industry[71] - The company has introduced three strategic large single products: "Shuanghuanglian Granules," "Xiaorensha Supting Granules," and "Midazolam Buccal Solution" to enhance its sales in respiratory and digestive systems, as well as in pediatric psychiatric medications[177] - The company aims to establish its liver protection tablets as its first CNY 1 billion-level golden product, with other key products also expected to regain growth momentum[76] Operational Efficiency and Management - Management emphasizes the importance of maintaining operational efficiency to mitigate risks associated with talent retention and management challenges[3] - The company aims to optimize its organizational structure and management processes to improve operational efficiency and support its strategic goals[161] - The company has implemented the OGSM management tool in 2022 to enhance strategic alignment and organizational efficiency[80] - The company is committed to building a new cooperative relationship with key customers to create a win-win ecosystem in the retail and medical sectors[162] Environmental Compliance and Sustainability - The company has implemented automatic online monitoring for COD and ammonia nitrogen, ensuring compliance with environmental standards[95] - The company has conducted regular monitoring of wastewater and air emissions to comply with environmental regulations[95] - The company has implemented measures to reduce carbon emissions, such as switching to external steam for production, significantly decreasing pollutant emissions[117] Subsidiaries and Investments - The company has established significant sales and procurement contracts, with ongoing performance as of the reporting period[108] - The company has completed the establishment of several subsidiaries, including Beijing Kuaihua Pharmaceutical Research Co., Ltd., with an investment of ¥54,000,000.00[126] - The company invested ¥20,000,000.00 in Gelerui (Wuxi) Nutrition Technology Co., Ltd., holding a 9.76% stake[124] - The company reported a total revenue of approximately CNY 1.16 billion and a net profit of around CNY 425.72 million from its subsidiary Heilongjiang Sunflower Pharmaceutical Co., Ltd. for the reporting period[154] Sales and Customer Relations - Total sales from the top five customers amounted to ¥2,634,179,855.92, representing 51.71% of the annual total sales[195] - Customer A contributed ¥1,729,891,431.91, accounting for 33.96% of the annual total sales[195] - Sales expenses increased by 8.40% year-on-year, totaling ¥1,274,273,752.65[198] - The OTC sales model accounted for 82.94% of total revenue, with a year-over-year growth of 13.95%[82] Financial Assets and Liabilities - The total investment amount as of the reporting period was ¥179,646,200.00, a decrease of 7.17% compared to the previous year[124] - The company reported a total of ¥2,658,000,000.00 in new purchases of financial assets during the reporting period[139] - The total amount of restricted assets at the end of the reporting period was ¥303,526.34, primarily related to the subsidiary's construction quality guarantee deposits[140] - The company reported a derivative investment of CNY 30 million in commodity futures, with a fair value change gain of CNY 1.13 million during the reporting period[170]

出席本次年度网上业绩说明会的人员有：公司董事长关玉秀女士、独立董事 施先旺先生，公司副总经理海洋先生、财务负责人吴春红女士，董事会秘书周广 阔先生。 证券代码：002737 证券简称：葵花药业 公告编号：2023-015 葵花药业集团股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"）于2023年4月12日披露公司 2022年年度报告。为便于广大投资者更加深入、全面的了解公司年度经营情况， 公司定于2023年5月4日（星期四）15：00–17：00在全景网举办2022年度网上业 绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆全景 网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 2023 年 4 月 11 日 1 为提升本次交流的针对性，现就本次年度业绩说明会提前向投资者公开征集 问题，投资者可于 2023 年 5 月 4 日星期四 15:00 前访问 https://ir.p5w.net/zj/，或扫描 ...

证券代码：002737 证券简称：葵花药业 葵花药业集团股份有限公司投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |----------------|--------------------------|---------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中国民族证券有限责任公司 田俊峰 | | 人员姓名 | | 中国民族证券有限责任公司 韩秋月 | | | | 华商基金管理有限公司 陈恒 | | | | 建信基金管理公司 潘龙玲 | | | | 中国人寿资产管理有限公司 赵文龙 | | | | 上海泓湖投资管理有限公司 况晓 | | | | 天弘基金管理有限公司 刘盟盟 | | | | 民生加银基金管理有限公司 蒯学章 | | 时间 | 2015 年 5 月 | 12 日 1 ...

证券代码：002737 证券简称：葵花药业 编号：2015-003 | --- | --- | --- | |----------------|--------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 调研单位：国联安基金管理有限公司 调研人员：焦阳 | | 人员姓名 | | 调研单位：博时基金管理有限公司 调研人员：田野 | | 时间 | 2015 年 5 月 26 | 日 13：00 至 15：00 | | 地点 | 公司二楼会议室 | | | 上市公司接待人 | 公司董事会秘书 | 艳女士 | | 员姓名 | 公司证券事务代表 | 周广阔先生 | | 投资者关系活动 | 交流主要内容： | | | 主要内容介绍 | 1 ...

证券代码：002737 证券简称：葵花药业 葵花药业集团股份有限公司投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |----------------|---------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中国国际金融有限公司 邹朋 | | | 人员姓名 | | 易方达基金管理有限公司 杨桢霄 | | 时间 | 2015 年 5 月 13 | 日 15：00 至 16： 30 | | 地点 | 公司四楼会议室 | | | 上市公司接待人 | 董事会秘书 | 田艳女士 | | 员姓名 | 证券事务代表 周广阔先生 | | | 投资者关系活动 | 交流主要内容： | | | 主要内容介绍 | 1、公司 ...